Bristol Myers Squibb Company will not launch its advanced melanoma combination treatment Opdualag (nivolumab plus relatlimab) in Germany because it does not believe it would win a favorable outcome in a benefit assessment.
Results of the benefit assessment are important as they subsequently influence the product’s final price.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?